John Sentz, DO
Pulmonary Disease · Richmond, VANPI 1497074561
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.8%), education and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by AstraZeneca at 29.5% of the total.
Across 623 payments — averaging $31.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Intuitive Surgical$5K
- GSK$2K
- Amgen$679
- Actelion Pharmaceuticals US, Inc.$621
- Grifols USA, LLC$601
- plus $5K from 31 others
What the payments were for
- Speaking & faculty fees$4,25022%
- Travel & lodging$7364%
- Food & beverage$10,15852%
- Education$4,46023%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 63 | $5,789 |
| Intuitive Surgical | 9 | $4,805 |
| GSK | 175 | $1,776 |
| Amgen | 35 | $679 |
| Actelion Pharmaceuticals US, Inc. | 23 | $621 |
| Grifols USA, LLC | 26 | $601 |
| Boehringer Ingelheim | 33 | $549 |
| Regeneron Healthcare Solutions, Inc. | 24 | $533 |
| Mallinckrodt Hospital Products Inc. | 15 | $460 |
| Genentech USA, Inc. | 30 | $452 |
| Sanofi | 26 | $447 |
| Insmed, Inc. | 23 | $353 |
| Mylan Specialty L.p. | 22 | $307 |
| ANI Pharmaceuticals, Inc. | 10 | $306 |
| Novartis | 19 | $295 |
| United Therapeutics Corporation | 15 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $220 |
| Pfizer | 11 | $212 |
| Electromed, Inc. | 12 | $153 |
| Merck | 7 | $148 |
| Bayer | 6 | $110 |
| Inogen, Inc. | 3 | $64 |
| Sanofi-aventis U.S. LLC | 1 | $57 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Philips North America LLC | 3 | $47 |
| Baxter Healthcare | 2 | $42 |
| Covidien LP | 3 | $40 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Paratek Pharmaceuticals, Inc. | 2 | $27 |
| Atricure, Inc. | 1 | $26 |
| La Jolla Pharmaceutical Company | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Covis Pharma GmbH | 1 | $17 |
| Vifor Pharma, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Pulmonx Corporation | 1 | $14 |
| Sandoz | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$19,604 in reported general payments places this provider in the 85th percentile of 317 pulmonary disease providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 729 | $565,728 |
| OfevNintedanib Esylate | 16 | $135,007 |
| Breo ElliptaFluticasone/Vilanterol | 210 | $119,034 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 127 | $107,288 |
| Dupixent PenDupilumab | 16 | $60,341 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 91 | $56,291 |
| XolairOmalizumab | 16 | $55,703 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 69 | $35,034 |
| Spiriva RespimatTiotropium Bromide | 49 | $34,587 |
| SymbicortBudesonide/Formoterol Fumarate | 68 | $19,685 |
| XareltoRivaroxaban | 23 | $18,069 |
| Wixela InhubFluticasone Propion/Salmeterol | 108 | $17,116 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 584 | $14,814 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 93 | $12,386 |
| Pirfenidone | 16 | $12,239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $1,776 | $729,5991,039 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $549 | $225,885156 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $5,789 | $133,753213 claims |
| MerckDulera | $148 | $9,86430 claims |
| Teva Pharmaceuticals USA, Inc.Qvar Redihaler, Proair Respiclick | $55 | $7,52948 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 317 pulmonary disease providers in Virginia.
Other pulmonary disease in Richmond
- Sujoy GillRichmond$296K
- Patricia SimeRichmond$113K
- Shilpa JohriRichmond$37K
- Apostolos PerelasRichmond$31K
- Glenn GiesselRichmond$14K
- Nauman ChaudaryRichmond$13K
- Michael MistrettaRichmond$13K
- Steven NathanFalls Church$1.5M
- Omar MinaiHopewell$1.3M
- Rabih HalabiFalls Church$604K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.